Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis
(2019)
Journal Article
Pearson, R. G., Masud, T., Blackshaw, E., Naylor, A., Hinchcliffe, M., Jeffery, K., Jordan, F., Shabir-Ahmed, A., King, G., Lewis, A. L., Illum, L., & Perkins, A. C. (2019). Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis. Pharmaceutics, 11(6), Article 265. https://doi.org/10.3390/pharmaceutics11060265
Nasal delivery of large peptides such as parathyroid 1-34 (PTH 1-34) can benefit from a permeation enhancer to promote absorption across the nasal mucosa into the bloodstream. Previously, we have published an encouraging bioavailability (78%), relati... Read More about Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis.